drugset / Trial / NCT00017264

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT00017264

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of atrasentan in treating patients who have progressive or recurrent malignant glioma.

Timeline

Start
2002-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Atrasentan Other / unclassified 70 mg Oral
Subject Atrasentan Other / unclassified 90 mg Oral